IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference

IDEAYA Biosciences (NASDAQ: IDYA) will present at the 44th Annual J.P.

Rhea-AI Summary

IDEAYA Biosciences (NASDAQ: IDYA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 3:45 PM PT (6:45 PM ET).

Presentation by Yujiro S. Hata, Chief Executive Officer, followed by an analyst-hosted Q&A with Anupam Rama, Managing Director, J.P. Morgan. A live audio webcast will be available via the company's Investors/Events webpage, with a replay accessible for 30 days after the event.

Argus Jan 5 session

+3.22% close to close Open Argus

Details

News Market Reaction – IDYA

On Jan 5, the day this news came out, IDYA closed 3.22% above the previous close.

Data tracked by StockTitan Argus for the Jan 5 session.

Key Figures

Conference date: January 12, 2026 Presentation time PT: 3:45 PM PT Presentation time ET: 6:45 PM ET +1 more

Conference date

January 12, 2026

J.P. Morgan Healthcare Conference presentation date

Presentation time PT

3:45 PM PT

Scheduled start time for management presentation

Presentation time ET

6:45 PM ET

Eastern Time equivalent for presentation

Webcast replay window

30 days

Duration replay will be accessible after live event

Historical Context

5 past events · Latest: Dec 11

5 events

1. Dec 11

   Pivotal trial enrollment

   24h Move

   -0.2%

   Completed enrollment of 435 patients in OptimUM-02 Phase 2/3 trial.

2. Dec 10

   IND submission

   24h Move

   -1.3%

   Submitted IND for IDE574 targeting Phase 1 trial initiation.

3. Dec 04

   IND clearance

   24h Move

   +4.7%

   Received FDA IND clearance for IDE034 ADC from Biocytogen license.

4. Dec 01

   IND clearance detail

   24h Move

   -3.7%

   Detailed IDE034 IND clearance and target tumor types, plus co-expression data.

5. Nov 28

   Equity inducement grant

   24h Move

   -0.7%

   Granted 17,600 stock options to a new hire under inducement plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Jargon Translator

antibody-drug conjugate

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

Inducement Plan

An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

precision medicine

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 44th Annual J.P. Morgan Healthcare Conference.

44th Annual J.P. Morgan Healthcare Conference
Monday, January 12^th, 2026, at 3:45 PM PT (6:45 PM ET)

• Presentation by Yujiro S. Hata, Chief Executive Officer, IDEAYA Biosciences, followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan

A live audio webcast of the presentation and Q&A session will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcast will be accessible for 30 days following the live event.

About IDEAYA Biosciences

IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer.  Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease.  We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications.  Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K filed on February 18, 2025.

Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-participation-at-the-44th-annual-jp-morgan-healthcare-conference-302651807.html

SOURCE IDEAYA Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will IDEAYA (IDYA) present at the J.P. Morgan Healthcare Conference?

IDEAYA will present on Monday, January 12, 2026 at 3:45 PM PT (6:45 PM ET).

Who will present for IDEAYA (IDYA) at the January 12, 2026 session?

Yujiro S. Hata, Chief Executive Officer, will present, followed by an analyst-hosted Q&A with Anupam Rama.

How can investors access IDEAYA's (IDYA) live webcast on January 12, 2026?

A live audio webcast will be available under the company's Investors/Events webpage at https://ir.ideayabio.com/events or through the conference host.

Will IDEAYA's (IDYA) webcast be available after the live presentation?

Yes. A replay of the webcast will be accessible for 30 days following the live event.

Will there be a Q&A during IDEAYA's (IDYA) J.P. Morgan presentation?

Yes. The presentation will be followed by an analyst-hosted Q&A with Anupam Rama from J.P. Morgan.

What is the ticker symbol for IDEAYA Biosciences referenced for investor searches?

The company's ticker symbol is IDYA on NASDAQ.